HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes.

AbstractBACKGROUND:
Platelet glycoprotein IIb/IIIa inhibitors reduce the rate of death or myocardial infarction among patients with acute coronary syndromes without persistent ST-segment elevation, but their effects may depend on plasma concentrations. We tested whether the addition of lamifiban, titrated to achieve target plasma concentrations, to standard care would improve clinical outcomes.
METHODS AND RESULTS:
We randomized 5225 patients at 389 centers in 29 countries to receive a bolus and </=72-hour infusion of lamifiban or placebo, adjusted for renal function, with aspirin and heparin. The primary end point was the composite of death, myocardial infarction, or severe, recurrent ischemia at 30 days. Baseline characteristics did not differ significantly by treatment. The primary end point occurred in 11.8% of lamifiban-treated patients and in 12.8% of placebo-treated patients (OR, 0.914; 95% CI, 0.769 to 1.087; P=0.329). Bleeding was more common in lamifiban-treated patients, but intracranial hemorrhage was not increased. Among the subgroup who had plasma lamifiban concentrations measured, 91% had a concentration >18 ng/mL at steady state, but their outcomes did not differ from those with lower concentrations.
CONCLUSIONS:
Lamifiban showed no significant effects on clinical outcomes in patients with non-ST-elevation acute coronary syndromes, despite achievement of adequate plasma concentrations.
AuthorsGlobal Organization Network (PARAGON)-B Investigators
JournalCirculation (Circulation) Vol. 105 Issue 3 Pg. 316-21 (Jan 22 2002) ISSN: 1524-4539 [Electronic] United States
PMID11804986 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Acetates
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Tyrosine
  • lamifiban
Topics
  • Acetates (administration & dosage, adverse effects, blood, therapeutic use)
  • Acute Disease
  • Aged
  • Coronary Disease (blood, drug therapy, mortality)
  • Double-Blind Method
  • Endpoint Determination
  • Female
  • Hemorrhage (etiology)
  • Humans
  • Incidence
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Myocardial Infarction (epidemiology)
  • Platelet Aggregation Inhibitors (administration & dosage, analysis, blood, therapeutic use)
  • Platelet Glycoprotein GPIIb-IIIa Complex (antagonists & inhibitors)
  • Syndrome
  • Titrimetry
  • Treatment Outcome
  • Tyrosine (administration & dosage, adverse effects, analogs & derivatives, blood, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: